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Abstract 
Purpose: The incidence of non-melanoma skin cancer (NMSC) has been increasing over the past 30 years. There 
are different treatment options and surgical excision is the most frequent treatment due to its low rates of recurrence. 
Radiotherapy is an effective alternative of surgery, and brachytherapy (BT) might be a better therapeutic option due 
to high radiation dose concentration to the tumor with rapid dose fall-off resulting in normal tissues sparing. The aim 
of this review was to evaluate the local control, toxicity, and cosmetic outcomes in NMSC treated with high-dose-rate 
BT (HDR-BT).
Material and methods: In May 2016, a systematic search of bibliographic database of PubMed, Web of Science, 
Scopus, and Cochrane Library with a combination of key words of “skin cancer”, “high dose rate brachytherapy”, 
“squamous cell carcinoma”, “basal cell carcinoma”, and “non melanoma skin cancer“ was performed. In this systematic 
review, we included randomized trials, non-randomized trials, prospective and retrospective studies in patients affect-
ed by NMSC treated with HDR-BT. 
Results: Our searches generated a total of 85 results, and through a process of screening, 10 publications were select- 
ed for the review. Brachytherapy was well tolerated with acceptable toxicity and high local control rates (median: 97%). 
Cosmetic outcome was reported in seven study and consisted in an excellent and good cosmetic results in 94.8% of 
cases.
Conclusions: Based on the review data, we can conclude that the treatment of NMSC with HDR-BT is effective with 
excellent and good cosmetics results, even in elderly patients. The hypofractionated course appears effective with very 
good local disease control. More data with large-scale randomized controlled trials are needed to assess the efficacy 
and safety of brachytherapy. 
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Purpose 
The incidence of skin cancer has been increasing over 
the past 30 years and currently 2-3 million new cases are 
diagnosed worldwide every year. Non-melanoma skin 
cancer (NMSC) is the most common skin malignancy 
(95%) and in recent years its incidence has been increas-
ing rapidly, even in young populations [1,2]. The develop-
ment of NMSC is due to a combination of environmental, 
genetic, and phenotypic factors [3,4]. Basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC) are the two 
most common subtypes: about 75-80% of all NMSC are 
characterized by the presence of BCC, 15-20% of these ma-
lignancies present SCCs, while 1% show a mixed pheno-
type [5]. There are different treatment options for NMSC 
such as surgery, cryotherapy, laser therapy (recommend-
ed only for shallow and early SCC), topical chemotherapy, 
photodynamic therapy, and radiotherapy (RT). Surgical 
excision is the most frequent treatment due to its low rates 
of recurrence, reported less than 5% [6,7,8,9,10]. In addi-
tion, RT is often used to treat NMSC and, specifically, dif-
ferent techniques can be used such as superficial X-rays, 
electron beams, megavoltage photons, and low-dose-rate 
(LDR) or high-dose-rate (HDR) brachytherapy (BT). Usu-
ally, the treatment options are chosen based on the institu-
tional resources and the specialist’s experiences. 
Electronic brachytherapy (EBT) is a new technique 
of radiotherapy, which delivers low-energy radiation 
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at a high-dose-rate through an applicator placed on the 
skin. Due to introduction of new devices that are com-
patible for use with the equipment of EBT (such as Xoft® 
Axxent®, Zeiss® INTRABEAM® and Elekta® Esteya®) 
and the commercialization of electronic BT, has attracted 
considerable interest in the BT treatment of small skin tu-
mors in last years. 
Compared to the other radiotherapy technique, HDR-
BT might be a better therapeutic option due to essential 
advantages such as high radiation dose concentration 
into the clinical target volumes (CTV), rapid dose fall-off 
at target periphery, optimal sparing of normal tissues in 
sensitive structures, shorter treatment time, and the use 
of hypofractionated course [11,12,13,14,15,16,17]. 
High-dose-rate BT is often delivered in the form of 
a surface mold but can also be delivered through use 
of a custom mold, Leipzig applicator, Valencia appli-
cator, or a variety of other techniques. Moreover, HDR 
brachytherapy technique allows to treat with curative 
doses some localizations (such as cancer on face skin, 
near eyes and nose) with excellent and good cosmetic 
outcomes [18,19,20,21,22,23,24,25,26]. 
The role of HDR brachytherapy using 192Ir source 
and surface applicators 
The development in the late 1960s of the HDR bra-
chytherapy afterloader, a robotic controller for auto-
mated insertion and removal of the radioactive source 
through catheters placed in or near the tumor, greatly 
improved radiation protection and simplified the deliv-
ery of the source. Most of NMSC brachytherapy today 
is delivered with HDR brachytherapy afterloaders using 
192Ir. While there is little level I evidence for traditional 
radiotherapy in the management of NMSC, there is no 
level I evidence for HDR brachytherapy. However, sev-
eral retrospective and prospective studies with excel-
lent results and adequate follow-up have been reported 
[19,20,21,22,23,24,25,26]. 
At first, Svoboda et al. [18] in 1995 published a data 
of 106 lesions (76 patients) treated with high-dose-rate 
micro selectron afterloader using expanded silicone rub-
ber molds and 192Ir source. 
In the study, were used different hypofractionated 
regimens (12-22 Gy given in a single fractions, 27-30 Gy/ 
3 fractions, 30 Gy/5 fractions, 40 Gy/10 fractions, 46 Gy/ 
10 fractions, and 50 Gy given in 15 fractions), and no 
recurrences were observed after a median follow-up of 
9.6 months. Only G1-G2 acute and late toxicity was ob-
served, and 94.4 % of lesions had an excellent and good 
cosmetic outcome. 
In 1999, Köhler-Brock et al. [19] described the outcome 
of 520 lesions treated with HDR-BT using Leipzig appli-
cators. The dose prescribed was 30-40 Gy in 5-10 fractions 
with a local control of 92% after 10 years’ of follow-up. 
One year later, Guix et al. [20] described a standardized 
surface mold technique prospectively utilizing HDR 
brachytherapy in 236 NMSC lesions, and achieved 5-year 
local control of 98% with excellent treatment tolerance and 
no severe early or late complications. Similar results were 
reported by other authors [19,20,21,22,23,24,25,26,27, 
28,29,30] in their retrospective studies. Despite the poten-
tial interest in BT for the treatment of non-melanoma skin 
cancer, there are not a lot of randomized controlled trials, 
systematic reviews, and/or metanalyses in literature. 
The aim of this review was to systematically evaluate 
the available literature data regarding the local control, 
toxicity, and cosmetic outcomes in patients affected by 
non-melanoma skin cancer and treated with HDR-BT. 
Material and methods 
Search strategy 
In May 2016, we conducted a comprehensive literature 
search of the following electronic databases: PubMed, 
Web of Science, Scopus, and Cochrane library. The data-
bases were searched with a combination of key words for 
non-melanoma-skin cancer treated with HDR-BT; “skin 
cancer”, “high dose rate brachytherapy”, “squamous cell 
carcinoma”, “basal cell carcinoma”, and “non melanoma 
skin cancer “.
Study selection 
In this systematic review, we included randomized 
trials, non-randomized trials, prospective studies, retro-
spective studies, and case series in patients affected by 
NMSC treated with HDR-BT. Single case reports and 
small case series with less than 20 cases were excluded. 
Moreover, we excluded studies reporting on patients 
with diagnoses different from NMSC skin cancer and 
studies reporting only palliative intent of skin cancer. In 
case of duplicated datasets (e.g. multiple articles from the 
same study group or institution, related to the same treat-
ment on the same cohort of patient), we included only the 
work with the longest follow-up and the greatest number 
of patients. 
Data extraction and analysis 
Data extraction was performed by one reviewer 
and checked by a second reviewer. Two reviewers inde-
pendently studied the abstracts and full text of all retrieved 
papers to select suitable articles for the assessment; dis-
agreement about study to be included in this review were 
resolved by discussion between two reviewers who select-
ed independently the publications for the evaluation. 
We obtained the following information from each re-
port: author identification, year of publication, medical 
center, study design characteristics, study population, 
number of patients, age, sex, histological diagnoses, BT 
technique, total dose, dose for fraction, delivered dose, 
local control, toxicity, functional cosmetic outcome, and 
follow-up time. Finally, in order to compare clinical out-
come of different modalities of fractionated regimens 
used (total dose and dose for fraction), the biological ef-
fective dose (BED) was calculated. 
Regarding late and acute toxicities or cosmetic events, 
all studies selected for this review used CTCAE v4.0 
(Common Terminology Criteria for Adverse Events) tox-
icity scales [27], or Toxicity criteria of the Radiation Ther-
apy Oncology Group (RTOG) and the European Organi-
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zation for Research and Treatment of Cancer (EORTC) 
scales [31]. 
Statistical analysis 
Before data performing, an exploration phase of the 
data was carried out; the categorical data were described 
by frequency and percentage, whereas continuous data 
by mean, median, and range. If necessary, after data ex-
ploration, analysis and calculation of frequencies, medi-
an, and range was performed due to description of end- 
points of the review. 
All analyses were performed using the SPSS 22 tech-
nology. 
Results 
Our searches generated a total of 85 results, and 
through a process of screening, 10 publications were se-
lected for the review. Of 65 studies excluded for this re-
view, 22 were excluded due to duplicate data, 30 were 
excluded because they were not clinical trials but consist-
ed in review (24), letter to editor (1) or book chapter (5). 
Finally, 23 studies were excluded because they did not 
fulfil the inclusion criteria: different treatment technique 
(such as use of low dose rate BT, interstitial BCT, EBRT 
with LINAC), little number of patients, palliative treat-
ment, and diagnoses of melanoma skin cancer in majori-
ty of patients. Therefore, 10 studies fulfilled the inclusion 
criteria and were included in our review. The flowchart of 
systematic literature search process is shown in Figure 1. 
Overall, in 10 studies analyzed in this review, 1977 le-
sions (1870 patients) were treated; of them, the majority 
of lesions 65% consisted in BCC, 32.5% were SCC, and 
the reaming 2.5% consisted in mixed phenotype such as 
Kaposi’s sarcoma, lymphomas, melanomas, and Bowen’s 
disease. The median age of patients treated was 72 years 
old, and 61% (1141) of patients were male and 39% (729) 
were female. The characteristics of these studies included 
in the review are summarized in Table 1 and Table 2. 
Doses and fractionation 
Comparing with external beam radiation, HDR-BT 
has an advantage regarding deep and superficial doses. In 
fact, during HDR-BT, the dose remains on the surface and 
does not penetrate deeply with optimal sparing of normal 
tissues due to dose concentration into the clinical target 
volumes (CTV) and rapid dose fall-off at target periphery 
[10,11,12,13,14,15,16,17]. Published studies have mainly 
reported standard fractionation and hypofractionated 
brachytherapy regimens in patients treated with HDR-BT, 
and the biological effective dose (BED) was often calcu-
lated due to define the total dose and dose for fractions 
regimen for a better local control and acceptable late and 
acute toxicity [19,20,21,22,23,24,25,26,33,34,35,36,37]. 
Biological effective dose is an inherent part of the lin-
ear quadratic (LQ) model of radiation effects and estimates 
the true biological dose delivered by a particular combina-
tion of dose per fraction and total dose to a given tissue 
characterized by a specific a/b ratio. It is calculated by the 
equation BED = nd [1 + d(α/β)] where n – the number of 
fractions, d – the dose/fraction, and α/β – radio-sensitivity 
coefficients at the dose at which the linear and quadratic 
components (for early or late cell damage, respectively) 
of cells killed are equal [38,39]. The a/b ratios vary based 
on the tumor type. For example, squamous cell cancers 
with high cell proliferation are characterized by 10-30 α/β 
ratio, while breast cancer shows lower values (4-5 Gy) as 
well in prostate cancer (0.8-2.5 Gy) and melanoma malig-
nancies [39,40]. For NMSC, the alpha/beta ratios are ap-
proximately 10 Gy [39]; for SCC lesions, the α/β value is 
lower and it is reported at a value of 8.5 in different data 
in literature [41]. From the previous equation, it is evi-
dent that the BED will increase proportionally to the dose 
per fraction and inversely proportional to the α/β ratio. 
If the total dose is kept constant, the BED will increase if 
the dose per fraction is increased. For these reasons, it is 
important to perform BED calculations before clinical de-
cisions since different histological classes of cancers have 
different a/b ratios, leading to different clinical responses, 
despite not changing the total dose. 
Conventional fractionated regimes were reported by 
Guix et al. [20] data of 136 patients affected by NMSC and 
received a total dose of 60-65 Gy in 33 to 36 fractions. In this 
study, the mean age of patients was 67 years old (range, 
23-91), 5 years local control for all patients was 98%. 
Hypofractionated HDR brachytherapy regimens, 
which reduce the number of treatment fractions, com-
pared with the conventional regimen that involves 
around 30 and 35 fractions, have been shown to achieve 
very good local control without increased side effects or 
85 records identified through 
database searching:
SCOPUS database: 63
PubMed database: 22
Cochrane library: 0
22 records were removed due  
to duplicate articles
63 records identified after  
duplicate removed
33 clinical trials were identified
10 studies fulfill the inclusion 
criteria and were eligibility for 
review
30 records were excluded  
because were non clinical trials:
25 review
4 book chapter
1 letter to editor
23 records were excluded  
because did not fulfill  
the inclusion criteria: 
treatment technique, palliative 
treatment, diagnoses  
of melanoma
Fig. 1. Flow chart of systematic literature search process 
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reduced cosmetic results. Moreover, conventional frac-
tionated regimens have different disadvantages such us 
higher number of sessions, overall treatment duration, 
moving the patient to the hospital, which can lead to an 
increase of overall costs effective therapy. 
Different hypofractionated regimens with very good 
local control has been reported in literature [19,20,21,22, 
23,24,25,26,27,28,37,41,42]. Most commonly hypofraction-
ated course described consist in a total dose of 30-40 Gy, 
delivered in 5-10 fractions once/ twice per week (Köhler-
Brock et al. [19]), 36 Gy in 12 fractions (Gauden et al. [23]), 
47-57 Gy delivered in 3 times weekly (Arenas et al. [42]), 
40-50 Gy delivered in 7-8 fractions 2/3 time at week 
(Ghaly et al. [22], Delishaj et al. [26]), 42 Gy in 6 fractions 
delivered twice weekly (Tormo et al. [25]). Other hypo-
fractionated regimes reported in some studies consist in 
50-60 Gy given in 8-10 fractions and 50-60 Gy delivered 
in 5-6 fractions two time a week (Skowronek et al. [21]). 
Local control 
An excellent local control in patients with NMSC and 
treated with HDR-BT has been shown in different stud-
ies, and the local control rate is variable reported with 
a wide range from 83.3% [24] to 98-100% [18,22,25,26]. 
The main factors that may influence local control consist 
of total dose prescription, doses for fractions, dimension 
and depth of lesion, and histological type. Kanikowski 
[24] reported a recurrences rate of 16.7% after a median 
follow-up of 12 months in 497 patients with skin cancer 
treated by brachytherapy between November 1999 till 
April 2008 (Table 1 and 2). However, this study included 
patients who received palliative brachytherapy and pa-
tients previously treated with external beam radiation, 
which reported recurrences after treatment. The data re-
ported by Skowronek et al. [21] showed a recurrences rate 
of 8.9% (179 lesions treated) after a median follow-up of 
12 months but this study included 8 patients with skin 
metastases and receiving BT with palliative intent. 
Köhler-Brock et al. [19] reported a recurrence rate of 8% 
of 520 lesions treated with HDR-BT using Leipzig applica-
tors at the doses of 30-40 Gy in 5-10 after, 10 years follow-up. 
The study included Kaposi’s sarcoma, melanomas, and 
skin metastases. Finally, other studies [20,22,23,25,26] in-
cluding patients affected by NMSC treated with definitive 
HDR-BT, reported excellent local control rate of 98-100%. 
Table 2. Summary of studies where high-dose-rate brachytherapy was used for the treatment of non-melano-
ma skin cancer – part II 
Study
(year)
Prescription Follow-up
(median)
Local  
control (%) 
Recurrence
rate
Acute toxicity Late toxicity Cosmetic results 
Svoboda et al. [18] 
(1995)
– 9.2 months 100 No recur-
rence
G1-G2 (25.4%) G1-G2 (5.7%) Excellent 50%
Good 44.4%
Poor 5.6%
Köhler-Brock et al. [19]
(1999)
6-8 mm 10 years 92 8% G1-G2 G1-G2 –
Guix et al. [20] 
(2000) 
5 mm 5 years 98 2% G1-2 (57.6%) G1-G2 
(0.84%) 
Excellent 98%
Good 2%
Skowronek et al. [21] 
(2005) 
5 mm 12 months 91.1 8.9% G1-G2 (87.7%)
G3 (12.3%)
G1-G2 (54%)
G3 (3.4%)
–
Ghaly et al. [22] 
(2008)
Leipzig
appropriate 
depth
18 months 100 No recur-
rence  
(3 lesions 
persisted)
G1-G2 (82%) G1-G2 Excellent
Kanikowski [24]  
(2008)
Depth based 
on CT or  
3 mm
12 months 83.3 16.7% G1-G2 (91.1%)
G3 (8.9%)
G2 (17.1%)
G3 (4.9%)
Not observed
Gauden et al. [23] 
(2013) 
Leipzig
appropriate 
depth 
66 months 98 2% G1-G2 (80%) G1-G2 (20%) Poor 5.5% 
Fair 6.5% 
Good 26% 
Excellent 62% 
Tormo et al. [25] 
(2014) 
4 mm 47 months 97.8 2.2% G1 G1 Excellent
Delishaj et al. [26] 
(2015) 
4 mm 12 months 96.2 No recur-
rence  
(2 lesions 
persisted)
G1-G2 (63.2%) G1-G2 (19.3%) Excellent 86% 
Good 12.6% 
Fair 1.7% 
Arenas et al. [42] 
(2015) 
5 mm 33 months 95.12 4.88% G1-G2 (57.5%) 
G3 (40.3%) 
G4 (2.2%) 
G1-G2 (3.1%) 
G3 (2.2%) 
G4 (0.8%) 
Excellent/good 
82% 
Fair 13% 
Not available 5% 
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Overall, the median of local control rate after HDR 
brachytherapy in 10 studies analyzed was 97%. 
Adverse events and cosmetic results 
As reported in the literature, HDR brachytherapy 
treatment is very well tolerated with excellent cosmetic 
results despite applicators used (Lippizing applicators, 
Valencia applicators or custom made surface molds), to-
tal doses, and dose for fractions. Moreover, excellent cos-
metic outcomes and acceptable acute and late side events 
were observed even in elderly patients using hypofrac-
tionated regimen of 40-50 Gy delivered in 8-10 fractions 
2-3 time weekly [19]. As shown in Table 3, the most com-
mon early side-effects due to HDR-BT treatment are ery-
thema, edema, rash dermatitis, pruritus, desquamation, 
and in rare cases ulceration. Late side effects appear, as 
per definition, 6 months after HDR-BT treatment and of-
ten consist of atrophy, pigmentation change, hair loss, tel-
angiectasia fibrosis, and in rare cases ulceration (Table 3). 
RTOG morbidity scoring criteria [31]. 
According to toxicity criteria of the Radiation Ther-
apy Oncology Group (RTOG) and the European Orga-
nization for Research and Treatment of Cancer (EORTC), 
scale G1-G2 acute toxicities after HDR-BT varies widely 
from 24.5% [18] to 91.1% [24]. G3 RTOG/EORT acute 
toxicities has been reported in several studies in litera-
ture and they differ from 0% [19,20,22,23,25,26] to 40.3%, 
as reported by Arenas et al. [42]. Acute G4 toxicity was 
reported only in one study with a frequency of 2.2% 
[42]. The incidence of late toxicity reported in literature 
is lower than the incidence of acute toxicity. G1-G2 late 
Table 3. Radiation Therapy Oncology Group (RTOG) morbidity scoring criteria [31] 
Grading Acute toxicity Late toxicity 
G0 No change over baseline None 
G1 Follicular, faint or dull erythema, epilation,  
dry desquamation, decreased sweating 
Slight atrophy, pigmentation change, some hair loss 
G2 Tender or bright erythema, patchy moist desquamation, 
moderate edema 
Patch atrophy, moderate, telangiectasia, total hair loss, 
induration 
G3 Confluent, moist desquamation other than skin folds, 
pitting edema 
Market atrophy, gross telangiectasia, fibrosis 
G4 Ulceration, hemorrhage, necrosis Ulceration or necrosis 
Table 4. Cosmetic rating scale [31] 
Excellent No changes to slight atrophy or pigment 
change, or slight hair loss or no changes to 
slight induration or loss of subcutaneous fat 
Good Patch atrophy, moderate telangiectasia, and 
total hair loss; moderate fibrosis but asymp-
tomatic; slight field contracture with less 
than 10% linear reduction 
Fair Marked atrophy and gross telangiectasia; 
severe induration or loss of subcutaneous tis-
sue; field contracture greater than 10% linear 
measurement 
Poor Ulceration or necrosis 
toxicities differ from a minimum of 0.84% [20] to a max-
imum of 54% [21]. 
Overall, three studies [21,24,42] reported G3 late tox-
icity with frequencies of 2.2%, 3.4%, and 4.9%, respective-
ly; G4 late toxicity was described only by Arenas et al. 
[42] data in 0.8% of lesions treated as shown in Table 2. In 
Table 4, we present a cosmetic rating scale [31]. 
Finally, as reported in many studies in literature, the 
treatment of NMSC with HDR BT is associated with ex-
cellent cosmetic outcomes even in elderly patients, as re-
ported in our previous study [19,20,21,22,23,24,25,26,27]. 
On average, an excellent cosmetic result was report-
ed from approximately 62% [23] to 98-100% [20,22,25]; 
a good cosmetic result from 0-2% [20,25] to 26% [23]; 
a fair result from 0% [25] to 13% [27], and, finally, a poor 
cosmetic result was reported in a range wide from 0% 
[24,25,26] to 5.5% [23]. Overall, an excellent and good cos-
metic outcome consisted of 94.8% of cases. 
Discussion 
Surgery is often the primary treatment for NMSC le-
sions due to low rates of recurrence reported [6,7,8,9,10]. 
However, surgical treatment is an invasive procedure, 
and in elderly patients is not always feasible because 
of comorbidities, performance status, or lesion location 
(near the eyes, nose, and on facial skin). Typically, RT is 
the treatment of choice in this class of patients since sur-
gery might be accompanied with functional or cosmetic 
deficits. The development of new devices for small skin 
tumor treatment and the introduction of commercial 
electronic BT have attracted considerable interest for BT 
as a skin cancer treatment. Despite the new technologies 
available, few studies have focused on the treatment of 
NMSC with HDR-BT and hypofractionated regimes 
seems to be a valid option for the treatment of NMSC 
with very good local control, toxicity, and cosmetic re-
sult [19,20,21,22,23,24,25,26,33,34,35,36,37,43,44]. In 1999, 
Köhler-Brock et al. [19] described the outcome of 520 le-
sions treated with HDR-BT using Leipzig applicators. 
The dose prescribed was 30-40 Gy in 5-10 fractions, and 
after 10 years’ of follow-up, local control was 92% of the 
cases; only G1-G2 late and acute toxicities were observed. 
One year later, Guix et al. [20] reported the results of 236 
NMSC lesions treated with HDR-BT using custom-made 
surface molds, and after five years of follow-up, the local 
control was 98%. In addition, Gauden et al. [23] published 
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the data of 236 lesions, and the local control was 98% after 
36 months of follow-up. The total dose prescribed was 
36 Gy in 12 fractions, and no G3 or higher late or acute 
toxicities were observed. 
Hypofractionated course appears effective with very 
good local disease control and have different advantag-
es such us little number of fractions, overall shorter time 
of duration, reduction of times for moving the patient to 
the hospital, and feasible outpatient treatment regimen, 
which can lead to reduction of overall costs effective ther-
apy [36]. Comparable outcomes were reported by Bhat-
nagar [37], Tormo et al. [25], and Ballester-Sánchez et al. 
[28] with the use of hypofractionated course and Valencia 
applicators or HDR electronic BT with surface applica-
tors, which resulted in excellent local control, cosmetic 
results, and very low-grade toxicities. More recently, we 
reported our data [26] of 57 lesions in elderly patients re-
ceiving hypofractionated regimes at the dose of 40-50 Gy 
in 8-10 fractions (using Valencia applicator) with excel-
lent local control, cosmetic results with no G3 or higher 
acute or late toxicity. Finally, Haseltine et al. [29] report-
ed the data of 61 patients treated with HDR brachyther-
apy, hypofractionated external beam radiation therapy 
(EBRT), or standard fractionation EBRT in patients af-
fected by NMSC. After a median follow-up of 30 months, 
the local control was 81% and 2-year overall survival was 
89%. There was no statistical difference in local control, 
overall survival, cosmetic outcome, or toxicity between 
treatment modalities. 
Conclusions 
As seen in our review, HDR-BT, through use of a cus-
tom mold, Leipzig applicator, Valencia applicator, or 
a variety of other techniques, is an alternate radiation 
modality that may be valuable for treatment of selected 
NMSCs. Typically, HDR-BT is the treatment of choice in 
patients, in which surgery is not feasible because of co-
morbidities, performance status, or lesion location, and 
surgery might be accompanied with functional or cos-
metic deficits. Overall, the hypofractionated course ap-
pears to be effective with very good local disease control. 
Moreover, this cost-effective therapy shows high compli-
ance and a feasible outpatient treatment regimen, essen-
tial in elderly patients. Finally, more data with large-scale 
randomized/prospective controlled trials and longer 
follow-up are needed to assess the efficacy and safety of 
HDR-BT, and to compare it directly with external beam 
therapy as well as the differential cure rates of subtypes 
of BCC versus SCC. 
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